bioMerieux (OTCMKTS:BMXMF) Shares Gap Up – Here’s What Happened

bioMerieux (OTCMKTS:BMXMF)’s share price gapped up prior to trading on Tuesday . The stock had previously closed at $77.93, but opened at $82.78. bioMerieux shares last traded at $82.78, with a volume of 259 shares trading hands.

Wall Street Analysts Forecast Growth

BMXMF has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of bioMerieux in a report on Wednesday, June 17th. Piper Sandler assumed coverage on bioMerieux in a research report on Thursday, June 11th. They set a “neutral” rating on the stock. UBS Group cut shares of bioMerieux from a “buy” rating to a “neutral” rating in a research note on Monday, June 1st. Zacks Research raised shares of bioMerieux to a “hold” rating in a report on Tuesday, April 28th. Finally, Morgan Stanley cut shares of bioMerieux from an “overweight” rating to an “underweight” rating in a research report on Tuesday, June 23rd. Five research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, bioMerieux currently has a consensus rating of “Reduce”.

bioMerieux Price Performance

The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.48 and a current ratio of 2.39. The company has a 50-day moving average of $82.00 and a 200 day moving average of $103.58.

About bioMerieux

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.